Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triamcinolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 9/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | PGR | P06401 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | CYP2J2 | P51589 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.86 |
| ▸ | AR | P10275 | 2/20 | 0.86 |
| ▸ | MEN1 | O00255 | 1/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.86 |
| ▸ | APEX1 | P27695 | 1/20 | 0.86 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.86 |
| ▸ | IKBKB | O14920 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triamcinolone SCHEMBL1884154 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL9863653 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL1502196 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL14373318 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL8813577 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL24622562 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL601462 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL570639 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL22962813 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 | |
| Triamcinolone SCHEMBL4447 | 1.00 | NR3C1 (1.00) | NR3C1HIF1ACYP3A4LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | claimed |
| EP-1205218-B1 | Topical antipsoriaticum comprising urea, a corticoid and a desinfectant | BENKERT EUGEN GEORG DR MED DEN (DE) | 2004-03-31 | — | — | EP | claimed |
| US-20030060425-A1 | Immune modulation method using steroid compounds | BIOVIE INC. | 2003-03-27 | — | — | US | claimed |
| EP-1205218-A1 | Topical antipsoriaticum comprising urea, a corticoid and a desinfectant | Benkert, Eugen Georg, Dr.med.dent. (DE) | 2002-05-15 | — | — | EP | claimed |
| US-4344940-A | DERMATITIS | E. R. SQUIBB & SONS, INC. (US) | 1982-08-17 | — | — | US | claimed |
| US-4011317-A | STEROID DERIVATIVES | RORER ITALIANA S.P.A. (IT) | 1977-03-08 | — | — | US | claimed |
| EP-3013407-B1 | MEDICAL TREATMENT SYSTEM | VAPOROX INC (US) | 2024-01-24 | — | — | EP | disclosed |
| US-11744961-B2 | Portable medical treatment system and method of use | VAPOROX, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20210046001-A1 | PHARMACEUTICAL OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF | IMPRIMIS PHARMACEUTICALS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20210038592-A1 | PHARMACEUTICAL COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF | NOVEL DRUG SOLUTIONS LLC | 2021-02-11 | — | — | US | disclosed |
| EP-3024475-B1 | PHARMACEUTICAL COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION COMPRISING AN ANTIBACTERIAL AGENT AND AN ANTIINFLAMMATORY AGENT | HARROW HEALTH INC (US) | 2020-09-30 | — | — | EP | disclosed |
| US-20200179406-A1 | INJECTABLE LONG-ACTING SEMI-SOLID GEL FORMULATIONS | HUZHOU HUI ZHONG JI SHI BIOTECHNOLOGY CO., LTD (CN) | 2020-06-11 | — | — | US | disclosed |
| US-20200101241-A1 | PORTABLE MEDICAL TREATMENT SYSTEM AND METHOD OF USE | CURE CARE, INC. | 2020-04-02 | — | — | US | disclosed |
| US-20030083231-A1 | Blood cell deficiency treatment method | BIOVIE INC. | 2003-05-01 | — | — | US | disclosed |
| US-20030060425-A1 | Immune modulation method using steroid compounds | BIOVIE INC. | 2003-03-27 | — | — | US | disclosed |
| EP-1205218-A1 | Topical antipsoriaticum comprising urea, a corticoid and a desinfectant | Benkert, Eugen Georg, Dr.med.dent. (DE) | 2002-05-15 | — | — | EP | disclosed |
| US-5482934-A | Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions | ESPECIALIDADES LATINAS MEDICAMENTOS UNIVERSALES, S.A. (ELMU, S.A.) (ES) | 1996-01-09 | — | — | US | disclosed |
| US-4344940-A | DERMATITIS | E. R. SQUIBB & SONS, INC. (US) | 1982-08-17 | — | — | US | disclosed |
| US-RE29799-E | DERMATOSIS, ECZEMA, NEURODERMATITIS, IMPETIGO, PSORIASIS, PRURITUS, ERYTHEMA | J. URIACH & CIA S.A. (ES) | 1978-10-10 | — | — | US | disclosed |
| US-3971772-A | ANTINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060425-A1 | Immune modulation method using steroid compounds | HSD3B1, NR5A1, HSD17B1 | NR3C1 15/4885HIF1A 724/4885CYP3A4 126/4885 |
| US-20210046001-A1 | PHARMACEUTICAL OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF | PDE6A, PDE6C, PDE6B | NR3C1 886/4885HIF1A 4651/4885CYP3A4 1927/4885 |
| US-20030083231-A1 | Blood cell deficiency treatment method | THPO, HPGDS, MPL | NR3C1 43/4885HIF1A 1462/4885CYP3A4 1381/4885 |
| US-20210038592-A1 | PHARMACEUTICAL COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF | PDE6C, PDE6A, MYOC | NR3C1 4047/4885HIF1A 3951/4885CYP3A4 1210/4885 |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | RECQL, GSS, DDX17 | NR3C1 104/4885HIF1A 1076/4885CYP3A4 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.